CHI Launches Podcast Highlighting Recent Data Findings on FDA Drug Lag

--(BUSINESS WIRE)-- California Healthcare Institute:

WHO:

   

David Gollaher, Ph.D., CHI President and CEO

Simon Goodall, The Boston Consulting Group Partner and Managing Director

 

WHAT:

In CHI’s most recent podcast series, Gollaher and Goodall discuss the findings of a recent CHI report: “Competitiveness and Regulation: The FDA and the Future of America’s Biomedical Industry.”

 

In recent years, there has been a dramatic shift of clinical trials and product launches by U.S. firms to Europe. Inefficiency at the FDA has led to American inventions being made available to patients and physicians in other countries first. This has also pushed jobs and revenues offshore, helping competitive nations gain experience in scaling up new biopharmaceutical and medical technology products. Importantly, though, patients are losing access to cutting-edge treatments.

 
WHEN: Monday, June 20, 2011
 
HOW:

To download the podcast, visit www.chi.org and click on “Multimedia” or visit iTunes. To subscribe to the series click on the RSS Feed.

 
ABOUT CHI:

CHI represents more than 250 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.



CONTACT:

California Healthcare Institute
Nicole Beckstrand
858-456-8881
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.